LAMP2 and myeloid sarcoma: Serum IGFBP7 had a greater AUC (0.945) than CSF IGFBP7 (0.890), serum LAMP2 (0.720), and CSF LAMP2 (0.396), which implies the potential relevance of IGFBP7 in MS categorization; conversely, serum IGFBP7 was more appropriate for use MS phenotypes than CSF IGFBP7 in clinical practice.